Ana Oaknin
安娜·奥克宁
MD, PhD
Head, Gynecologic Cancer Programme; Senior Medical Oncologist妇科癌症项目负责人；高级医学肿瘤学家
👥Biography 个人简介
Ana Oaknin, MD, PhD is Head of the Gynecologic Cancer Programme at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, and is one of Europe's leading translational oncologists specializing in immunotherapy for gynecologic cancers. She has been a key investigator in the KEYNOTE and GARNET trials establishing pembrolizumab and dostarlimab in endometrial and cervical cancer, and has led early-phase studies evaluating novel immune-oncology combinations across all gynecologic tumor types. Dr. Oaknin is active in ESGO, ESMO, and GOG leadership and is widely recognized for her contributions to developing immunotherapy as a standard treatment option in gynecologic oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GARNET Trial — Dostarlimab in Endometrial Cancer
Principal investigator in the GARNET trial establishing dostarlimab's efficacy in mismatch repair-deficient recurrent endometrial cancer, contributing to EMA and FDA approval of dostarlimab for this indication.
KEYNOTE-158 in Cervical Cancer
Key investigator in the KEYNOTE-158 basket trial cohort demonstrating pembrolizumab activity in recurrent/metastatic cervical cancer with PD-L1 expression, supporting accelerated FDA approval in this setting.
Novel Immunotherapy Combinations
Leads VHIO's early-phase gynecologic cancer program evaluating combinations of immune checkpoint inhibitors, antibody-drug conjugates, and targeted agents, with multiple INDs and phase I/II trials currently enrolling.
Representative Works 代表性著作
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY/ENGOT-EN6-NSGO)
New England Journal of Medicine (2023)
Phase III trial demonstrating dostarlimab plus chemotherapy improved PFS in advanced endometrial cancer, with pronounced benefit in MMR-deficient tumors.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Journal of Clinical Oncology (2019)
KEYNOTE-158 cohort data establishing single-agent pembrolizumab activity in PD-L1-positive recurrent cervical cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 安娜·奥克宁 的研究动态
Follow Ana Oaknin's research updates
留下邮箱，当我们发布与 Ana Oaknin（Vall d'Hebron University Hospital and Institute of Oncology (VHIO)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment